Pulse Biosciences to Participate in the Jefferies Healthcare Conference

May 24, 2021 12:00 UTC

 

 
 

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Jefferies Virtual Healthcare Conference.

Management is scheduled to present at 12:30pm PT on Wednesday, June 2, 2021. Interested parties may access the live and recorded webcast on the “Investors” section of the Company’s website at www.pulsebiosciences.com.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The company’s proprietary Nano-Pulse Stimulation (NPS™) technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.

To stay informed about the CellFX System, please visit CellFX.com and sign-up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Contacts

Investors:
Pulse Biosciences
Sandra Gardiner, EVP and CFO
510.241.1077
IR@pulsebiosciences.com
or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

Media:
Tosk Communications
Nadine D. Tosk
504.453.8344
nadinepr@gmail.com or
press@pulsebiosciences.com

 
 

Source: Pulse Biosciences, Inc.

Back to news